Poinsettia announced that Ruiteng Biotech, a wholly-owned subsidiary of the company, holds 13.45% of the shares of Arthrosi in the United States. Recently, Arthrosi plans to sign a merger and acquisition agreement with Sobi US. Sobi US plans to acquire 100% of Arthrosi's shares with a down payment of US$950 million and a milestone payment of up to US$550 million. Once the deal is completed, the company will no longer hold shares in Arthrosi.

Poinsettia announced that Ruiteng Biotech, a wholly-owned subsidiary of the company, holds 13.45% of the shares of Arthrosi in the United States. Recently, Arthrosi plans to sign a merger and acquisition agreement with Sobi US. Sobi US plans to acquire 100% of Arthrosi's shares with a down payment of US$950 million and a milestone payment of up to US$550 million. Once the deal is completed, the company will no longer hold shares in Arthrosi.